December 2025

Efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis: 52-week results from SPROUT randomised control trial

Br J Dermatol 2025;193:1120–1127 Doi: 10.1093/bjd/ljaf305

Paller et al. evaluated the long-term efficacy and safety of apremilast in paediatric patients with moderate-to-severe plaque psoriasis through the 52-week Phase III SPROUT trial. The study assessed whether clinical responses were sustained after the placebo-controlled period and whether outcomes differed between treatment sequences.

Keywords:

Whole food diet induces remission in children and young adults with mild to moderate Crohn's disease and is more tolerable than exclusive enteral nutrition: A randomized controlled trial

Gastroenterology 2025;169:1462–74 Doi: 10.1053/j.gastro.2025.06.011

Aharoni-Frutkoff et al. demonstrated that tasty & healthy (T&H) ‘diet’ showed better tolerability than exclusive enteral nutrition (EEN) for inducing remission in mild to moderate CD, while positively affecting the microbiome. Authors explored the tolerability and effectiveness of the T&H diet compared with EEN in children and young adults with mild to moderate uncomplicated CD.

Keywords:

A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab

BMC Rheumatology 2025;9:139 Doi: 10.1186/s41927-025-00594-9

In this real-world study, Baraliakos, et al. SC IFX demonstrated clinical effectiveness in both
r- and nr-axSpA, with consistent results across diverse patient characteristics. Both physicians and patients reported high satisfaction with no new safety concerns. Authors assessed the real-world outcomes of CT-P13 SC (SC IFX) as treatment for both r- and
nr-axSpA.

Keywords:

Upadacitinib in psoriatic arthritis with prior TNF-inhibitor failure: a 56-week real-world study

Clin Exp Rheumatol. 2025; Advance online publication Epub ahead of print Doi: 10.55563/clinexprheumatol/gniy9i

Bakay et al. report  that upadacitinib (UPA) demonstrated sustained efficacy across musculoskeletal and skin domains in PsA patients with prior inadequate response to TNF inhibitors, with a safety profile consistent with previous reports.  Authors conducted a retrospective, single-centre observational study evaluating musculoskeletal disease activity, psoriasis, and patient-reported outcomes following initiation of UPA.

Keywords:

The impact of glucocorticoids on the efficacy of JAK inhibitors or non-TNF-targeted biologics in rheumatoid arthritis

Rheumatology 2025 Doi: 10.1093/rheumatology/keaf612 Epub ahead of print

Salvato et al. showed that the combination of GC and b/tsDMARDs did not provide additional clinical benefits after 12 months, suggesting that chronic GC use alongside advanced therapies should be avoided. Authors assessed the impact of chronic oral low-dose GCs on the efficacy and retention rates of JAKi compared to other mechanisms of action (OMA) therapies in a cohort of RA patients with inadequate response to TNFi.

Keywords:

Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial

RMD Open 2025;11:e006213 Doi: 10.1136/rmdopen-2025-006213

Kameda et al. reported that UPA treatment sustained efficacy with no new safety signals identified through 5 years of treatment and is a long-term treatment option for Japanese patients with RA and an inadequate response to csDMARDs. Authors present the full 5-year efficacy and safety data for upadacitinib obtained in the SELECT-SUNRISE study.

Keywords:

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: Real-world results from the Italian multicenter UPARAREMUS study

Arthritis Research & Therapy 2025;27:203 Doi: 10.1186/s13075-025-03671-z

Diamanti et al. showed that after 12 months of UPA treatment, a substantial proportion of RA patients achieved combined clinical and US remission, independent of prior bDMARD use or monotherapy. In the preliminary data from the UPARAREMUS study, authors reported efficacy of UPA in achieving both clinical and US remission up to 24 weeks in 60 RA patients.

Keywords:

November 2025

Association of BMI, BMR, BSA, and body weight with psoriasis severity and treatment response: Evidence from a real-world cohort

J Transl Med 2025;23:1129 Doi: 10.1186/s12967-025-07130-w

Xu et al. showed that elevated BMI, BSA, body weight, and basal metabolic rate are associated with more severe PsO and diminished treatment efficacy, especially for those treated with biologics. Authors investigated the associations of BMI, basal metabolic rate, BSA, and body weight with baseline PsO severity and therapeutic response across different treatment modalities.

Keywords:

Clinical efficacy, drug retention and recurrence of ixekizumab across psoriasis severities: A multicenter retrospective analysis of 354 patients

J Dermatol Treat 2025;36:2562299 Doi: 10.1080/09546634.2025.2562299

Qiao et al. showed that ixekizumab demonstrated superior efficacy in mild-moderate versus severe PsO, suggesting greater benefit with early biologic intervention. Authors compared clinical efficacy, relapse rates, and drug retention between mild-to-moderate and severe plaque PsO cohorts with different severity levels treated with Ixekizumab.

Keywords:

Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint

Crohn’s and Colitis 2025 Advance Access: 13 July 2025 Doi: 10.1093/ecco-jcc/jjaf124

Mirikizumab was evaluated for its ability to achieve disease clearance (DC) across two years in adults with moderately to severely active ulcerative colitis within the LUCENT trial programme. DC required concurrent symptomatic, endoscopic, and histologic remission.

Keywords: